CATALOGO DEI PRODOTTI DELLA RICERCA

PILOTTO, Sara
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 8.409
NA - Nord America 6.455
AS - Asia 5.195
SA - Sud America 835
AF - Africa 166
OC - Oceania 9
Continente sconosciuto - Info sul continente non disponibili 6
AN - Antartide 1
Totale 21.076
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.294
RU - Federazione Russa 4.141
SG - Singapore 2.094
CN - Cina 1.633
GB - Regno Unito 1.109
IT - Italia 692
BR - Brasile 671
HK - Hong Kong 574
DE - Germania 553
SE - Svezia 451
FR - Francia 382
IE - Irlanda 370
VN - Vietnam 336
FI - Finlandia 287
KR - Corea 160
NL - Olanda 118
CA - Canada 86
PL - Polonia 83
JP - Giappone 66
IN - India 65
ID - Indonesia 64
AR - Argentina 60
UA - Ucraina 47
MX - Messico 45
TG - Togo 42
BJ - Benin 37
ES - Italia 37
AT - Austria 34
ZA - Sudafrica 29
BD - Bangladesh 28
TR - Turchia 28
BE - Belgio 27
EC - Ecuador 22
MA - Marocco 20
CO - Colombia 19
VE - Venezuela 19
CZ - Repubblica Ceca 18
IQ - Iraq 15
IR - Iran 14
LT - Lituania 13
CL - Cile 12
PK - Pakistan 11
UZ - Uzbekistan 11
AE - Emirati Arabi Uniti 10
PY - Paraguay 10
PE - Perù 9
AZ - Azerbaigian 8
KZ - Kazakistan 8
PH - Filippine 8
AU - Australia 7
CH - Svizzera 7
NP - Nepal 7
SA - Arabia Saudita 7
TN - Tunisia 7
BO - Bolivia 6
HN - Honduras 6
KE - Kenya 6
LV - Lettonia 6
UY - Uruguay 6
AM - Armenia 5
CR - Costa Rica 5
EG - Egitto 5
EU - Europa 5
JO - Giordania 5
KG - Kirghizistan 5
RO - Romania 5
SK - Slovacchia (Repubblica Slovacca) 5
DK - Danimarca 4
IL - Israele 4
KH - Cambogia 4
LA - Repubblica Popolare Democratica del Laos 4
LK - Sri Lanka 4
AO - Angola 3
DZ - Algeria 3
JM - Giamaica 3
NO - Norvegia 3
PA - Panama 3
PS - Palestinian Territory 3
PT - Portogallo 3
SN - Senegal 3
TW - Taiwan 3
BG - Bulgaria 2
BM - Bermuda 2
DO - Repubblica Dominicana 2
GA - Gabon 2
GR - Grecia 2
LU - Lussemburgo 2
LY - Libia 2
MY - Malesia 2
NI - Nicaragua 2
SV - El Salvador 2
SY - Repubblica araba siriana 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BY - Bielorussia 1
CY - Cipro 1
EE - Estonia 1
GD - Grenada 1
Totale 21.052
Salva come PNG Salva come JPEG
Città #
Moscow 1.402
Dallas 989
Southend 901
Chandler 819
Singapore 810
Ashburn 659
Hong Kong 566
Dublin 369
Beijing 349
Woodbridge 298
Munich 269
Jacksonville 195
New York 183
Ann Arbor 181
Los Angeles 180
The Dalles 172
Verona 166
Lawrence 125
Princeton 125
Ho Chi Minh City 114
Wilmington 114
Helsinki 108
Jinan 105
Houston 83
São Paulo 76
Redondo Beach 75
London 72
Turku 72
Hanoi 66
Tianjin 66
Buffalo 65
Sindelfingen 64
Tokyo 61
Santa Clara 60
Shenyang 60
Redmond 59
Milan 57
Meda 55
Nanjing 54
Seoul 53
Columbus 50
Hebei 50
Seattle 43
Lomé 42
Warsaw 42
Amsterdam 40
Cotonou 37
Jakarta 37
Brooklyn 34
Guangzhou 34
Washington 34
Nanchang 33
Zhengzhou 32
Hangzhou 31
Kent 31
Rome 31
Frankfurt am Main 30
Nuremberg 30
San Francisco 30
Atlanta 29
Changsha 29
Haikou 29
Denver 28
Montreal 28
Stockholm 28
Brussels 27
Chicago 27
Council Bluffs 27
Ningbo 27
Boardman 25
Lappeenranta 25
Chennai 23
Dong Ket 22
Johannesburg 22
Phoenix 22
Toronto 22
Orem 21
Rio de Janeiro 21
Belo Horizonte 20
Taiyuan 20
Taizhou 20
Vienna 19
Boston 18
Falls Church 18
Falkenstein 17
Jiaxing 17
Biên Hòa 16
Fuzhou 16
Redwood City 16
Mexico City 15
Poplar 15
Curitiba 14
Haiphong 14
Maceió 13
Norwalk 13
Augusta 12
Bologna 12
Brno 12
Da Nang 12
Naples 12
Totale 11.811
Salva come PNG Salva come JPEG
Nome #
Immune checkpoint blockade therapy mitigates systemic inflammation and affects cellular FLIP-expressing monocytic myeloid-derived suppressor cells in non-progressor non-small cell lung cancer patients 271
Comprehensive molecular portrait using next generation sequencing of resected intestinal-type gastric cancer patients dichotomized according to prognosis 223
ALK gene copy number in lung cancer: Unspecific polyploidy versus specific amplification visible as double minutes 214
ALK/EML4 Fusion Gene May Be Found in Pure Squamous Carcinoma of the Lung 207
High-throughput mutation profiling identifies novel molecular dysregulation in high-grade intraepithelial neoplasia and early gastric cancers 206
"Running with cancer": A qualitative study to evaluate barriers and motivations in running for female oncological patients 204
An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer 185
ALK gene copy number gains in non-small-cell lung cancer: prognostic impact and clinico-pathological correlations 184
Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers 180
Prognostic impact of proliferation for resected early stage 'pure' invasive lobular breast cancer: Cut-off analysis of Ki67 according to histology and clinical validation 178
Next-generation repeat-free FISH probes for DNA amplification in glioblastoma in vivo: Improving patient selection to MDM2-targeted inhibitors 178
Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of Ki67 assay according to histology: prognostic relevance for resected early stage 'pure' and 'mixed' lobular breast cancer 170
Adjuvant Chemotherapy For Resected Non-Small-Cell Lung Cancer: Future Perspectives For Clinical Research 168
Impact of neoadjuvant single or dual HER2 inhibition and chemotherapy backbone upon pathological complete response in operable and locally advanced breast cancer: Sensitivity analysis of randomized trials 166
Deep vein thrombosis in SARS-CoV-2 pneumonia-affected patients within standard care units: Exploring a submerged portion of the iceberg 164
Neoadjuvant strategies for triple negative breast cancer: 'state-of-the-art' and future perspectives 163
Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma 162
Addressing the expected survival benefit for clinical trial design in metastatic castration-resistant prostate cancer: Sensitivity analysis of randomized trials 160
A multimodal approach to cancer-related cachexia: from theory to practice 160
The coming of ramucirumab in the landscape of anti-angiogenic drugs: potential clinical and translational perspectives 159
Organisational challenges, volumes of oncological activity and patients' perception during the severe acute respiratory syndrome coronavirus 2 epidemic 158
Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice 157
Gene expression profiling of lung atypical carcinoids and large cell neuroendocrine carcinomas identifies three transcriptomic subtypes with specific genomic alterations 154
Lung neuroendocrine tumours: deep sequencing of the four WHO histotypes reveals chromatin remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D 152
Preliminary results of PRINCiPe (predictors of resistance to immunotherapy with nivolumab [NIV]) study in advanced pretreated non-small cell lung cancer (APNSCLC), investigating the role of an immune genomic signature (IGS) including JAK2, JAK3, PIAS4, PTPN2, STAT3, IFNAR2 alterations 149
Abscopal effect and resistance reversion in nivolumab-treated non-small-cell lung cancer undergoing palliative radiotherapy: a case report 149
Advances towards the design and development of personalized non-small-cell lung cancer drug therapy. 148
Exercise prehabilitation in lung cancer: Getting stronger to recover faster 148
A Feasibility Study Investigating an Exercise Program in Metastatic Cancer Based on the Patient-Preferred Delivery Mode 146
Adjuvant therapy for resected early-stage small-cell lung cancer: is now time to rethink about that? 146
Psychological impact of Covid-19 pandemic on oncological patients: a survey in Northern Italy 145
A cross-sectional study evaluating the exercise discussion with oncologist during cancer consultation: the CONNECT study 144
A propensity score analysis exploring the impact of adjuvant chemotherapy (aCT) in a multi-center series of resected early stage pure invasive lobular breast carcinoma (ILC) 144
Tubulin inhibitors in non-small cell lung cancer: looking back and forward 142
Prognostic Impact of Preoperative Nutritional Risk in Patients Who Undergo Surgery for Pancreatic Adenocarcinoma 142
Integrating supportive care into the multidisciplinary management of lung cancer: we can't wait any longer 140
How the COVID-19 Pandemic Impacted on Integrated Care Pathways for Lung Cancer: The Parallel Experience of a COVID-Spared and a COVID-Dedicated Center 139
A narrative review on tumor microenvironment in oligometastatic and oligoprogressive non-small cell lung cancer: a lot remains to be done 138
Anti-Angiogenic Drugs and Biomarkers in Non-Small-Cell Lung Cancer: A 'Hard Days Night' 138
Risk Stratification Model for Resected Squamous-Cell Lung Cancer Patients According to Clinical and Pathological Factors 138
Anticipating EGFR Targeting in Early Stages of Lung Cancer: Leave No Stone Unturned 138
Prognostic model for advanced breast carcinoma with luminal subtype and impact of hormonal maintenance: Implications for post-progression and conditional survival 136
Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant Setting 136
Clinical implication of changes in body composition and weight in patients with early-stage and metastatic breast cancer 136
Development of Educational Print Materials for Physical Activity in Cancer: Evaluation of Readability and Suitability 136
MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapy 135
Characterization of Myeloid-derived Suppressor Cells in a Patient With Lung Adenocarcinoma Undergoing Durvalumab Treatment: A Case Report 135
Clinical results of randomized trials and 'real-world' data exploring the impact of Bevacizumab for breast cancer: opportunities for clinical practice and perspectives for research 133
Do immune checkpoint inhibitors need new studies methodology? 133
Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer 131
Evaluation of nutritional status in non-small-cell lung cancer: screening, assessment and correlation with treatment outcome 131
Maintenance or consolidation therapy in small-cell lung cancer: an updated systematic review and meta-analysis 130
Potential role of RICTOR copy number gain (CNG) as a key biomarker of mTOR activity: A comprehensive preclinical analysis in squamous cell lung cancer (SQLC) models 129
Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune system. 128
Infections and Immunotherapy in Lung Cancer: A Bad Relationship? 128
Exercise levels and preferences in cancer patients: a cross-sectional study 127
Platelet-derived growth factor receptor inhibitors for non-small cell lung cancer: is the odyssey over? 125
Exercise for counteracting post-acute COVID-19 syndrome in patients with cancer: an old but gold strategy? 125
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study 124
Exercise and anemia in cancer patients: could make the difference? 123
Muscle derangement and alteration of the nutritional machinery in NSCLC 121
Molecular predictors of EGFR-mutant NSCLC transformation into LCNEC after frontline osimertinib: digging under the surface 121
Necitumumab in the treatment of non-small-cell lung cancer: clinical controversies 119
Activity of EGFR TKIs in Caucasian Patients With NSCLC Harboring Potentially Sensitive Uncommon EGFR Mutations 119
A qualitative study exploring the experiences and perspectives of patients with cancer attending a 12-week exercise program 118
Surface CD52, CD84, and PTGER2 mark mature PMN-MDSCs from cancer patients and G-CSF-treated donors 117
Development of a nomogram for predicting pathological complete response in luminal breast cancer patients following neoadjuvant chemotherapy 116
Exercise oncology: It is time to make a change 116
Antibody-drug conjugates (ADCs) targeting TROP-2 in lung cancer 115
Prognostic Model for Resected Squamous-Cell Lung Cancer: External Multicenter Validation and Propensity Score Analysis exploring the Impact of Adjuvant and Neoadjuvant Treatment 115
Multidisciplinary lifestyle intervention to manage pancreatic cancer-related cachexia: a case report 114
Effect of exercise on functional capacity in patients with advanced cancer: A meta-analysis of randomized controlled trials 114
A cross-sectional study exploring the perception of exercise oncology in the Italian population 113
Combined Large Cell Neuroendocrine Carcinomas of the Lung: Integrative Molecular Analysis Identifies Subtypes with Potential Therapeutic Implications 113
Clinical meta-analyses of targeted therapies in adenocarcinoma. 113
Integrating the molecular background of targeted therapy and immunotherapy in lung cancer: a way to explore the impact of mutational landscape on tumor immunogenicity 113
Tracking occult pN2 disease after mediastinal dissection in early stage lung cancer. 113
Moving towards a customized approach for drug development: lessons from clinical trials with immune checkpoint inhibitors in lung cancer 113
Impact of exercise in patients with pancreatic cancer across different treatment phases: a systematic review 113
Characterizing the immune tumor microenvironment in ALK fusion-positive lung cancer: state-of-the-art and therapeutical implications 112
Final data of an Italian multicentric survey about counseling for smoking cessation in patients with diagnosis of a respiratory disease 111
Targeted next-generation sequencing identifies genomic abnormalities potentially driving the prognosis of early-stage invasive lobular breast carcinoma patients stratified according to a validated clinico-pathological model 111
PD-L1 for selecting non-small-cell lung cancer patients for first-line immuno-chemotherapy combination: a systematic review and meta-analysis 110
Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC 110
Physical activity and exercise in lung cancer care: will promises be fulfilled? 109
Avoiding chemotherapy for advanced nononcogene addicted NSCLC overexpressing PD-L1: Rule or option? 109
Efficacy and safety of afatinib for non-small-cell lung cancer: state-of-the-art and future perspectives 109
Plasmacytoid Dendritic Cell, Slan+-Monocyte and Natural Killer Cell Counts Function as Blood Cell-Based Biomarkers for Predicting Responses to Immune Checkpoint Inhibitor Monotherapy in Non-Small Cell Lung Cancer Patients 108
Genetic and non-genetic resistance mechanisms in non-small cell lung cancer harboring (non-ALK) oncogenic fusions 108
Targeting the epidermal growth factor receptor in solid tumors: focus on safety. 108
Predictive and prognostic effect of computed tomography-derived body composition analysis during neoadjuvant chemotherapy for operable and locally advanced breast cancer 107
Real-world outcomes according to treatment strategies in ALK-rearranged non-small-cell lung cancer (NSCLC) patients: an Italian retrospective study 107
Evidence-based tailored nutrition educational intervention improves adherence to dietary guidelines, anthropometric measures and serum metabolic biomarkers in early-stage breast cancer patients: A prospective interventional study 106
PTEN in Lung Cancer: Dealing with the Problem, Building on New Knowledge and Turning the Game Around 104
ARID1A mutational status in non-small cell lung cancer: from molecular pathology to clinical implications with a focus on the relationships with EGFR 103
Factors influencing physical activity in cancer patients during oncological treatments: a qualitative study 103
Kinesiology students' perception regarding exercise oncology: a cross-sectional study 102
Feasibility of a novel exercise program for patients with breast cancer offering different modalities and based on patient preference 101
Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non-small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy 101
Genetic, epigenetic and micro-environmental markers as predictors of prognosis, response and resistance to chemotherapy, targeted agents and immunotherapy in resected squamous cell lung carcinoma (SQLC). 100
Totale 13.673
Salva come PNG Salva come JPEG
Categoria #
all - tutte 81.450
article - articoli 79.858
book - libri 0
conference - conferenze 975
curatela - curatele 0
other - altro 288
patent - brevetti 0
selected - selezionate 0
volume - volumi 329
Totale 162.900
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021350 0 0 0 0 0 88 29 16 24 24 122 47
2021/20221.080 60 292 8 119 39 27 31 58 46 23 95 282
2022/20232.327 144 261 206 411 196 539 19 137 262 21 97 34
2023/20241.661 59 95 158 166 212 267 99 139 39 117 229 81
2024/20254.541 230 184 209 791 148 200 201 192 708 351 435 892
2025/20268.913 848 732 1.103 2.374 3.708 148 0 0 0 0 0 0
Totale 21.395